A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Integration of new or experimental treatment options and new approaches to clinical trials.
Michael A. Quinn,Jacobus Pfisterer,Elisabeth Åvall-Lundqvist,Michael A. Bookman,David D.L. Bowtell,A Casado,Andrés Cervantes,Seija Grénman,P Harper,Amit M. Oza,Sergio Pecorelli,Eric Pujade-Lauraine,Edward L. Trimble,Paul Vasey,Uwe Wagner +14 more
TL;DR: Integration of new or experimental treatment options and new approaches to clinical trials are integrated into existing clinical trials.
Journal ArticleDOI
Emerging growth factor receptor antagonists for ovarian cancer treatment
TL;DR: Targeting essential growth pathways in the tumour and associated microenvironment, is fundamental for biomarker discovery and towards achieving significant improvements in response.
Journal ArticleDOI
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
Sandro Pignata,Amit M. Oza,Geoff Hall,Beatriz Pardo,Radosław Mądry,David Cibula,Jaroslav Klat,Ana Montes,Rosalind Glasspool,Nicoletta Colombo,Imre Pete,Ana Herrero,Margarita Romeo,Rumyana Ilieva,Constanta Timcheva,Massimo Di Maio,Alan Barnicle,Rosie Taylor,Zahid Bashir,Andrew R Clamp +19 more
TL;DR: Findings highlight that PSROC pts, beyond those with a gBRCAm, can benefit from maintenance olaparib, and suggest similar activity in non-BRCA HRRm pts.
Journal ArticleDOI
986TiPA randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy
A. Gonzalez Martin,L.A. Rojas,Patricia S. Braly,J. Barter,David M. O'Malley,Amit M. Oza,Ashley Haggerty,Christof Vulsteke,Diane Provencher,Whitney Graybill,Ying Fei Li,I Malinowska,Mansoor Raza Mirza,Ignace Vergote,Bhavana Pothuri,Bradley J. Monk +15 more
Proceedings ArticleDOI
3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
Johanne I Weberpals,Amit M. Oza,Domenica Lorusso,Giovanni Scambia,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Andrew R Clamp,Alexandra Leary,Robert W. Holloway,M. Amenedo Gancedo,P.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Susana Banerjee,Jesús García-Donas,Elizabeth M. Swisher,T. Cameron,Lara Maloney,Sandra Goble,Robert L. Coleman,Jonathan A. Ledermann +23 more
TL;DR: Rucaparib maintenance for recurrent ovarian cancer (rOC) significantly improved investigator-assessed PFS and postprogression efficacy outcomes versus placebo regardless of biomarker status and there was a trend for better outcomes across all endpoints in patients with BRCA1 and BRCa2 mutations.